Royalty Pharma RPRX Interest coverage
Interest coverage at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
Based on trailing twelve months.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's interest coverage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's interest coverage?
- Royalty Pharma (RPRX) reported interest coverage of 4.7× in Q1 2026.
- How has Royalty Pharma's interest coverage changed year-over-year?
- Royalty Pharma's interest coverage decreased by 38.7% year-over-year, from 7.7× to 4.7×.
- What is the long-term trend for Royalty Pharma's interest coverage?
- Over 2 years (2021 to 2025), Royalty Pharma's interest coverage has grown at a -22.2% compound annual growth rate (CAGR), from 41.6× to 25.2×.
- What does interest coverage mean?
- How many times the company's operating profit covers its interest bill.
- How do you interpret interest coverage?
- Higher is safer; below ~2× is a warning that earnings provide little cushion against the debt burden. Debt-free companies have no interest expense and the ratio is left blank.
- How does interest coverage compare across companies?
- Comparable across leveraged non-financials; less relevant for net-cash companies with negligible interest.